Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -7.89 Million SEK | -191.34% |
| 2022 | 8.63 Million SEK | 237.53% |
| 2021 | -6.28 Million SEK | -27.86% |
| 2020 | -4.91 Million SEK | 5.58% |
| 2019 | -5.2 Million SEK | 8.07% |
| 2018 | -5.66 Million SEK | -4.71% |
| 2017 | -5.4 Million SEK | -6.94% |
| 2016 | -5.05 Million SEK | -23.86% |
| 2015 | -4.08 Million SEK | -433.09% |
| 2014 | -765.57 Thousand SEK | -1147.29% |
| 2013 | 73.1 Thousand SEK | 406.34% |
| 2012 | -23.86 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -2.61 Million SEK | -26.91% |
| 2024 Q2 | -2.05 Million SEK | -18.27% |
| 2024 Q1 | -1.74 Million SEK | 21.01% |
| 2023 Q2 | -2.48 Million SEK | -25.14% |
| 2023 Q4 | -2.2 Million SEK | -70.59% |
| 2023 Q1 | -1.98 Million SEK | -113.17% |
| 2023 FY | -7.56 Million SEK | -187.61% |
| 2023 Q3 | -1.29 Million SEK | 48.09% |
| 2022 Q2 | -2.24 Million SEK | -8.57% |
| 2022 Q3 | -2.13 Million SEK | 5.0% |
| 2022 Q4 | 15.09 Million SEK | 806.46% |
| 2022 FY | 8.63 Million SEK | 237.53% |
| 2022 Q1 | -2.07 Million SEK | -17.91% |
| 2021 Q4 | -1.75 Million SEK | -15.33% |
| 2021 Q2 | -1.57 Million SEK | -10.97% |
| 2021 FY | -6.28 Million SEK | -27.86% |
| 2021 Q1 | -1.42 Million SEK | 13.59% |
| 2021 Q3 | -1.52 Million SEK | 3.48% |
| 2020 FY | -4.91 Million SEK | 5.58% |
| 2020 Q2 | -891.65 Thousand SEK | 32.06% |
| 2020 Q4 | -1.64 Million SEK | -54.88% |
| 2020 Q3 | -1.06 Million SEK | -19.2% |
| 2020 Q1 | -1.31 Million SEK | 59.8% |
| 2019 Q3 | -1.83 Million SEK | -37.21% |
| 2019 FY | -5.2 Million SEK | 8.07% |
| 2019 Q2 | -1.34 Million SEK | -18.21% |
| 2019 Q1 | -1.13 Million SEK | 25.49% |
| 2019 Q4 | -3.26 Million SEK | -77.5% |
| 2018 Q4 | -1.52 Million SEK | -28.41% |
| 2018 FY | -5.66 Million SEK | -4.71% |
| 2018 Q3 | -1.18 Million SEK | 21.97% |
| 2018 Q2 | -1.51 Million SEK | -6.02% |
| 2018 Q1 | -1.43 Million SEK | 8.34% |
| 2017 Q2 | -1.58 Million SEK | -17.63% |
| 2017 FY | -5.4 Million SEK | -6.94% |
| 2017 Q3 | -909.52 Thousand SEK | 42.62% |
| 2017 Q1 | -1.34 Million SEK | 25.83% |
| 2017 Q4 | -1.56 Million SEK | -71.88% |
| 2016 Q1 | -1.09 Million SEK | 58.77% |
| 2016 FY | -5.05 Million SEK | -23.86% |
| 2016 Q4 | -1.81 Million SEK | -76.17% |
| 2016 Q3 | -1.03 Million SEK | 7.1% |
| 2016 Q2 | -1.11 Million SEK | -1.26% |
| 2015 Q2 | -520.43 Thousand SEK | -81.85% |
| 2015 Q1 | -286.19 Thousand SEK | 2.56% |
| 2015 Q3 | -615.36 Thousand SEK | -18.24% |
| 2015 FY | -4.08 Million SEK | -433.09% |
| 2015 Q4 | -2.65 Million SEK | -332.13% |
| 2014 FY | -765.57 Thousand SEK | -1147.29% |
| 2014 Q4 | -293.71 Thousand SEK | 0.0% |
| 2013 FY | 73.1 Thousand SEK | 406.34% |
| 2012 FY | -23.86 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AcuCort AB | -13.24 Million SEK | 40.441% |
| AlzeCure Pharma AB (publ) | -38.26 Million SEK | 79.376% |
| BioGaia AB (publ) | 440.9 Million SEK | 101.79% |
| Enzymatica AB (publ) | -48.06 Million SEK | 83.582% |
| Enorama Pharma AB (publ) | -41.83 Million SEK | 81.139% |
| Gabather AB (publ) | -9.47 Million SEK | 16.709% |
| Klaria Pharma Holding AB (publ.) | -14.68 Million SEK | 46.247% |
| Moberg Pharma AB (publ) | -27.46 Million SEK | 71.267% |
| Nanexa AB (publ) | -76.62 Million SEK | 89.702% |
| Newbury Pharmaceuticals AB (publ) | -14.07 Million SEK | 43.948% |
| ODI Pharma AB | -1.34 Million SEK | -488.161% |
| Orexo AB (publ) | -109.5 Million SEK | 92.794% |
| Probi AB (publ) | 11.32 Million SEK | 169.708% |
| Swedencare AB (publ) | 173.2 Million SEK | 104.556% |
| Swedish Orphan Biovitrum AB (publ) | 4.65 Billion SEK | 100.169% |
| Vivesto AB | -356.71 Million SEK | 97.788% |